Outcome of Sarcoidosis

Clinics in Chest Medicine

Volumn 29, Issue 3, 2008, Pages 565-574

  Nagai, Sonoko ^a   Handa, Tomohiro ^b   Ito, Yutaka ^b   Ohta, Kousuke ^a   Tamaya, Manabu ^c   Izumi, Takateru ^a,b  

^a Clinical Research Center   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

DETERIORATION; DISEASE COURSE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HUMAN; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SARCOIDOSIS; TH1 CELL; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; MORBIDITY; PROGNOSIS; RECURRENCE; SARCOIDOSIS; SURVIVAL RATE; WORLD HEALTH;

EID: 44649184044     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2008.03.006     Document Type: Review

References (50)

1. Siltzbach L.E. Sarcoidosis: clinical features and management. Med Clin North Am 51 (1967) 483-502
2. American Thoracic Society (ATS), The European Respiratory Society (ERS), and the World Association of sarcoidosis and other granulomatous disorders (WASOG). Statement of sarcoidosis. Am J Respir Crit Care Med 160 (1999) 736-755
3. Nagai S., Shigematsu M., Hamada K., et al. Clinical courses and prognoses of pulmonary sarcoidosis. Curr Opin Pulm Med 5 (1999) 293-298
4. Mana J., Gomez-Vaquero C., Montero A., et al. Lofgren's syndrome revisited: a study of 186 patients. Am J Med 107 (1999) 240-245
5. Baughman R.P., Judson M.A., Teirstein A., et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. Q J Med 99 (2006) 307-315
6. Turner-Warwick M. Treatment of pulmonary sarcoidosis. State of the art. In: Grassi C., Rizzato G., and Pozzi E. (Eds). Sarcoidosis and other granulomatous disorders. Proceedings of the XI World Congress on Sarcoidosis, and other granulomatous disorders. Milan, 1987. International Congress series. 756 (1988), Excerpta Medica, Amsterdam 621-629
7. Lynch III J.P., Kazerooni E.A., and Gay S.E. Pulmonary sarcoidosis. Clin Chest Med 18 (1997) 755-785
8. Shah L. Lung transplantation in sarcoidosis. Semin Respir Crit Care Med 28 1 (2007) 134-140
9. Katz S. Clinical presentation and natural history of sarcoidosis. In: Fanburg B.L. (Ed). Sarcoidosis and other granulomatous diseases of the lung (1983), Marcel Dekker, New York 3-36
10. Hunninghake G.W., Gilbert S., Pueringer R., et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 149 (1994) 893-898
11. Gibson G.J., Prescott R.J., Muers M.F., et al. British Thoracic Society Sarcoidosis Study; effects of long- term corticosteroid treatment. Thorax 51 (1996) 238-247
12. Takada K., Ina Y., Noda M., et al. The clinical course and prognosis of patients with severe, moderate, or mild sarcoidosis. J Clin Epidemiol 46 4 (1993) 359-366
13. Gottlieb J.E., Israel H.L., Steiner R.M., et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 111 (1997) 623-631
14. Mana J., Montero A., Vidal M., et al. Recurrent sarcoidosis: a study of 17 patients with 24 episodes of recurrence. Sarcoidosis Vasc Diffuse Lung Dis 20 (2003) 212-221
15. Vestbo J., and Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis. Sarcoidosis 11 (1994) 123-125
16. Baughman R.P., Winget D.B., Bowen E.H., et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 14 (1997) 154-158
17. Lewis N.M., Mortelliti M.P., Yeager Jr. H., et al. Clinical bronchiectasis complicating pulmonary sarcoidosis: case series of seven patients. Sarcoidosis Vasc Diffuse Lung Dis 19 (2002) 154-159
18. Burton C.M., Milman N., Carlsen J., et al. The Copenhagen National Lung Transplant Group: survival after single-lung, double-lung, and heart-lung transplantation. J Heart Lung Transplant 24 (2005) 1834-1843
19. Shorr A.F., Davies D.B., and Nathan S.D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 124 (2003) 922-928
20. Gideon N.M., and Mannino D.M. Sarcoidosis mortality in the United States, 1979-1991; an analysis of multiple-cause mortality data. Am J Med 100 (1996) 423-427
21. Yamaguchi M., Hosoda Y., Sasaki I., et al. Epidemiological study on sarcoidosis in Japan. Recent trends in incidence and prevalence rates and changes in epidemiological features. Sarcoidosis 6 (1989) 138-146
22. Iwai K. Morbid anatomy of sarcoidosis in Japan. Sarcoidosis 9 Suppl 1 (1992) 9-15
23. Perry A., and Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 119 2 (1995) 167-172
24. Neville E., Walker A.N., and James D.G. Prognostic factors predicting the outcome of sarcoidosis. An analysis of 818 patients. Q J Med 52 208 (1983) 525-538
25. Judson M.A., Baughman R.P., Teirstein A.S., et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 16 (1999) 75-86
26. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case-control study of sarcoidosis. Am J Respir Crit Care Med 164 (2001) 1885-1889
27. Nagai S., Baughman R.P., Costabel U., et al., WASOG task group. Clinical phenotypes of sarcoidosis. Japanese Journal of Sarcoidosis and Other Granulomatous Disorders 25 (2005) 93-98
28. Judson M.A., Hirst K., Iyengar S.K., et al. Comparison of sarcoidosis phenotypes among affected African American siblings. Chest 130 (2006) 855-862
29. Schischmanoff P.O., Naccache J.M., Carrere A., et al. Progressive pulmonary sarcoidosis is associated with overexpression of TYK2 and p21Wafl/Cip1. Sarcoidosis Vasc Diffuse Lung Dis 23 (2006) 101-107
30. Rybicki B.A., Sinha R., Iyengar S., et al. Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study. Genes Immun 8 (2007) 379-386
31. Veltkamp M., Grutters J.C., van Moorsel C.H., et al. Toll-like receptor (TLR) 4 polymorphism Asp299Gly is not associated with disease course in Dutch sarcoidosis patients. Clin Exp Immunol 145 (2006) 215-218
32. Berlin M., Fogdell-Hahn A., Olerup O., et al. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 156 (1997) 1601-1605
33. Sato H., Grutters J.C., Pantelidis P., et al. HLA-DQB *0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 27 (2002) 406-412
34. Yamaguchi E., Itoh A., Hizawa N., et al. The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis. Chest 119 (2001) 753-761
35. Baughman R.P., Engel P.J., Meyer C.A., et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23 2 (2006) 108-116
36. Handa T., Nagai S., Izumi T., et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129 5 (2006) 1246-1252
37. Nunes H., Humbert M., Capron F., et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics, and prognosis. Thorax 61 1 (2006) 68-74
38. Sulica R., Teirstein A.S., Kakarla S., et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 128 3 (2005) 1483-1489
39. Shigemitsu H., Nagai S., and Sharma O.P. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med 13 5 (2007) 434-438
40. Shorr A.F., Helman D.L., Davies D.B., et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 25 5 (2005) 783-788
41. Padia S.A., Budev M., Farver C.F., et al. Intravascular sarcoidosis presenting as pulmonary vein occlusion: CT and pathologic findings. J Thorac Imaging 22 3 (2007) 268-270
42. Fisher K.A., Serlin D.M., Wilson K.C., et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 130 5 (2006) 1481-1488
43. Baughman R.P. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 9 Suppl 2 (2007) s8
44. Preston I.R., Klinger J.R., Landzberg M.J., et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 120 3 (2001) 866-872
45. Johns C.J., Schonfeld S.A., Scott P.P., et al. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann N Y Acad Sci 465 (1986) 702-712
46. Sugisaki K., Yamaguchi T., Nagai S., et al. Clinical characteristics of 195 Japanese sarcoidosis patients treated with oral corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 20 (2003) 222-226
47. Petinalho A., Tukiainen P., Haahtela T., et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 121 (2002) 24-31
48. Lower E.E., and Baughman R.P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 155 (1995) 846-851
49. Baughman R.P., and Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 21 (2004) 43-48
50. Baughman R.P., Drent M., Kavuru M., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174 7 (2006) 795-802